Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Tolerability of Tanogitran (BIBT 986 BS) in Healthy Males
NCT02254083Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2003
- Primary completion
- May 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tanogitran in thromboembolism (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma, Concentration of the analyte at the end of drug infusion and 20 more. Started Feb 2003; status: completed.
02
Drugs
tanogitran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02254083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254083.